Skip to main content
logo
Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
6.46
+0.18 (2.87%)
Oct 27, 2026, 2:59 PM EDT - Market open

Cartesian Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
1.482.838.9126110.7885.08
Revenue Growth
43.96%-92.81%49.64%-76.53%30.21%-
Gross Profit
-66.91-55.24-5.99-39.6638.416.34
Operating Income
-98.66-86.71-35.52-74.4114.54-4.6
Net Income
-151.89-130.3-77.42-257.2635.38-25.69
Earnings Per Share
-5.61-5.02-4.48-49.762.98-6.74
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
147.61125.14212.6176.91134.64.74
Total Debt
63.8512.6813.9810.9637.931.28
Net Cash (Debt)
83.75112.46198.6365.9696.683.46
Net Cash Growth
-43.02%-43.38%201.15%-31.78%2698.18%-
Net Cash Per Share
3.094.3311.4412.7619.880.91

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-76.53-73.94-23.67-51.16-31.63-60.38
Capital Expenditures
-2.08-5.45-9.09-0.21-1.2-1.09
Free Cash Flow
-78.61-79.4-32.77-51.37-32.83-61.47
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
---15.40%-152.50%34.66%19.21%
Operating Margin
-6679.69%-3099.93%-91.27%-286.13%13.12%-5.40%
Pretax Margin
-10906.16%-4987.31%-198.23%-917.97%31.39%-11.43%
Profit Margin
-10283.75%-4658.63%-198.97%-989.31%31.94%-30.19%
FCF Margin
-5322.41%-2838.58%-84.21%-197.53%-29.64%-72.25%

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
133.9767.0311.844.12--